Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine

Huang ShuiWen; Liu BaoRong; Chen MingSheng; Lin Chun; Zhou Rui; Yang HuiAn; Jiang XiaoYan; Pan Chen; Li DongLiang

doi:10.3969/j.issn.1001-5256.2016.07.014

Issue 7

Jul. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(7): 1287-1291

PDF( 1571 KB)

Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine

DOI: 10.3969/j.issn.1001-5256.2016.07.014

Research funding:

Received Date: 2016-01-28
Published Date: 2016-07-20

Abstract

Abstract

Objective To investigate the establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B( CHB) patients treated with telbivudine,since early virologic response can predict the long- term efficacy of nucleotide analogues.Methods A total of 135 CHB patients who visited Mengchao Hepatobiliary Hospital of Fujian Medical University from January 2007 to August 2014 were enrolled and treated with telbivudine( 600 mg qd) for at least 24 weeks. Follow- up was performed once every 2 weeks,and the patients' baseline data and data measured during treatment were recorded. The t- test was used for comparison of continuous data between groups,the chi- square test was used for comparison of categorical data between groups,and the Cox proportional hazards regression model was used to analyze the influencing factors for early virologic response and establish the predictive model. Results The patients without a family history of hepatitis B virus( HBV) infection( P = 0. 000 3) and with high baseline levels of total bilirubin( TBil)( P = 0. 002 6)and aspartate aminotransferase( AST)( P = 0. 007 4) and a low HBV DNA load( P = 0. 002 3) tended to show early virologic response.The predictive model was established based on these variables,and the risk score( R) of CHB patients was calculated. The CHB patients with R > 0. 85 were more likely to achieve early virologic response. Conclusion The model established based on the four variables of family history,baseline TBil level,baseline AST level,and HBV DNA level can well predict early virologic response in previously untreated CHB patients treated with telbivudine.
- hepatitis B,
- chronic,
- telbivudine,
- proportional hazards models

FullText(HTML)

References(14)

References

[1]XU JB.AntiviraI effect of telbivudine in patients with chronic hepatitis B[J].J Pract Hepatol,2010,13(5):374-375.(in Chinese)徐俊斌.替比夫定治疗慢性乙型肝炎的疗效观察[J].实用肝脏病杂志,2010,13(5):374-375.

[2]LIU XD.Telbivudine[J].Chin J Med Chemistry,2007,17(5):335.(in Chinese)刘晓东.替比夫定(telbivudine)[J].中国药物化学杂志,2007,17(5):335.

[3]NGUYEN MH,KEEFFE EB.Chronic hepatitis B:early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides[J].J Viral Hepat,2009,16(3):149-155.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Clin JHepatol,2011,19(1):13-24.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.

[5]YOU CR,LEE SW,JANG JW,et al.Update on hepatitis B virus infection[J].World J Gastroenterol,2014,20(37):13293-13305.

[6] SHI XF,HONG GL.A survey of the status of hepatitis B virus infection in people undergoing physical examination[J].Int J Virol,2015,22(Suppl):58-59.(in Chinese)石新芳,鸿嘎鲁.健康体检人员乙肝病毒感染状况调查[J].国际病毒学杂志,2015,22(Suppl):58-59.

[7]YU YQ,CHEN SL,ZHANG WH.Research progress in combination therapy with pegylated interferon and nucleos(t)ide analogues in treatment of chronic hepatitis B[J].J Clin Hepatol,2015,31(9):1513-1519.(in Chinese)喻一奇,陈少隆,张文宏.核苷和核苷酸类药物联合聚乙二醇干扰素治疗慢性乙型肝炎的研究进展[J].临床肝胆病杂志,2015,31(9):1513-1519.

[8]HUANG MX,WU YK,SHI H,et al.Comparation of the efficacy of telbivudine and entecavir for treating 144 weeks of patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(1):32-36.(in Chinese)黄明星,吴元凯,时红,等.替比夫定和恩替卡韦治疗慢性乙型肝炎144周的疗效比较[J/CD].中华实验和临床感染病杂志:电子版,2014,8(1):32-36.

[9]WU Y,HAN L,YUAN YF.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13.(in Chinese)吴岩,韩璐,原永芳.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13.

[10]SUN DC,CHEN L,WU ZY,et al.Current status of diagnosis and treatment of chemotherapy-associated hepatitis B virus reactivation[J].Chin J Clin Pharmacol,2014,19(5):584-590.(in Chinese)孙德聪,陈丽,吴志勇,等.化疗相关乙肝病毒再激活的诊治现状[J].中国临床药理学与治疗学,2014,19(5):584-590.

[11]LIAW YF,GANE E,LEUNG N,et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.

[12]YUEN MF,FONG DY,WONG DK,et al.Hepatitis B virus DNAlevels at week 4 of lamivudine treatment predict the 5-year ideal response[J].Hepatology,2007,46(6):1695-1703.

[13]BROOK MG,KARAYIANNIS P,THOMAS HC.Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy?A statistical analysis of predictive factors[J].Hepatology,1989,10(5):761-763.

[14]MARINOS G,NAOUMOV NV,WILLIAMS R.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection[J].Hepatology,1996,24(5):991-995.

Relative Articles

[1]	Zhiru WANG, Wenjing ZHAO, Xi CHEN. Effect and mechanism of gallic acid on the proliferation， migration， invasion， and apoptosis of human hepatocellular carcinoma HepG2 cells[J]. Journal of Clinical Hepatology, 2025, 41(3): 493-498. doi: 10.12449/JCH250315
[2]	Junzhe CAI, Songbai LIU, Xiaobin FEI, Peng LIU, Changhao ZHU, Xing WANG, Yaozhen PAN. Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(5): 989-996. doi: 10.12449/JCH240519
[3]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[4]	Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
[5]	Lu Qian, Cheng Xin, Xia ZhenGuo, Chen Zhong. Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 592-595. doi: 10.3969/j.issn.1001-5256.2020.03.024
[6]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[7]	Xiao ErHui, Ning HuiBin, Kang YueHua, Yin Hui, Ma Li, Mao ZhongShan, Zhao Yan, Shang Jia. Downregulation of miR-196b in regulating the growth and apoptosis of hepatoma cells by targeting nuclear apoptosis-inducing factor 1[J]. Journal of Clinical Hepatology, 2020, 36(10): 2230-2235. doi: 10.3969/j.issn.1001-5256.2020.10.014
[8]	Zhang Yang, Chen ShuYing, Xu GuangRu. Effect of extracellular ubiquitin on the proliferation,invasion,and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(6): 1289-1292. doi: 10.3969/j.issn.1001-5256.2020.06.020
[9]	Zhu YueKun, Zhao XianQi, Wang DaWei, Zhang Wei, Tian MaoLin, Li ZhengTian, Zhao Long, Li Chao, Jiang HongChi. Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2018, 34(12): 2614-2618. doi: 10.3969/j.issn.1001-5256.2018.12.021
[10]	Li YingYing, Zhan LiFen, Ceng ZheChao, Xu Shen. Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action[J]. Journal of Clinical Hepatology, 2018, 34(4): 784-788. doi: 10.3969/j.issn.1001-5256.2018.04.018
[11]	Sha Liang, He JianBo, Li KeZhi, Chen Chuang, Huang Shan, Zhao YinNong, Lian Fang, Wu GuoBin. Influence of specific down-regulation of LKB1 expression on invasion and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(5): 875-879. doi: 10.3969/j.issn.1001-5256.2017.05.016
[12]	Geng YaJun, Li ShuDong, Liu ShenZheng, Ren JianJun, Zhang Tong. Inhibitory effect of microRNA-149-5p in the proliferation and migration of HepG2 and Bel-7402 hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(6): 1126-1130. doi: 10.3969/j.issn.1001-5256.2017.06.022
[13]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[14]	Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
[15]	Du SenRong, Mao XiaoRong, Xiao Ping, Chen Hong. Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2[J]. Journal of Clinical Hepatology, 2015, 31(6): 943-946. doi: 10.3969/j.issn.1001-5256.2015.06.027
[16]	Xu Li, Ma KeXin, Dong Bing, Liu HaiWang, Liu QinLong, Gao ZhenMing, Sun DeGuang, Zhang RiXin, Wang HaiBo, Wang LiMing, Liang Rui. Regulatory effect of miRNAs on apoptosis, migration, and cell cycle of hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(7): 554-557.
[17]	Shen Bo, Nie YuQiang. Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro[J]. Journal of Clinical Hepatology, 2013, 29(9): 702-706. doi: 10.3969/j.issn.1001-5256.2013.09.018
[18]	Jia XiaoLi, Shi JuanJuan, Feng Ting, Cheng YanAn, Wang Rui, Liu JingKun, Dang ShuangSuo. Effects of guggulsterone on proliferation and apoptosis of HepG2 human hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(6): 452-455.
[19]	Tai BoJun, Yao Min, Gu Xing, Shi Yun, Yu DanDan, Chen Jie, Zheng WenJie, Yao DengFu, Lu ShaoLin. Effects of silencing glypican- 3 gene transcription on proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2013, 29(11): 863-866. doi: 10.3969/j.issn.1001-5256.2013.10.015
[20]	Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	李慧萍，郑雪琴，赵群，唐建江. Ⅲ型前胶原、Ⅳ型胶原、层黏连蛋白和透明质酸酶在诊断肝纤维化程度中的应用. 检验医学与临床. 2019(05): 666-668 .
2.	吴一鸣，高树兴，殷新光. 核素首次通过法测定肝动脉血流指数预测日本血吸虫病肝纤维化程度?. 中国肝脏病杂志(电子版). 2018(02): 49-54 .
3.	柯叶芳，高国生，朱喆，陈必成. 血清腺苷脱氨酶对慢性HBV感染者显著肝纤维化的诊断价值. 临床肝胆病杂志. 2018(04): 760-763 . 本站查看
4.	吴一鸣，高树兴，殷新光. 测定肝动脉血流指数预测血吸虫肝纤维化的临床研究. 世界华人消化杂志. 2018(07): 434-440 .
5.	胡烨，张国. 肝纤维化诊断及其严重程度评估. 实用肝脏病杂志. 2017(01): 13-16 .
6.	王娉娉，杨芬. 生物组织弹性成像方法及其新技术进展. 激光生物学报. 2016(06): 501-508+514 .
7.	牟文倩，李春艳，陈延平. 继发性血色病1例报告. 临床肝胆病杂志. 2016(09): 1789-1790 . 本站查看

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2306) PDF downloads(454)

Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine

DOI: 10.3969/j.issn.1001-5256.2016.07.014